产品编号 :
Cas No. :
| 包装规格 | 纯度 | 目录价 | 会员专享价 | 库存 | 数量 |
|---|---|---|---|---|---|
| 5mg | 95% | 询价 | |||
| 25mg | 95% | 询价 | |||
| 50mg | 95% | 询价 | |||
| 100mg | 95% | 询价 | |||
| 250mg | 95% | 询价 |
| 包装规格 | 纯度 | 目录价 | 会员专享价 | 库存 | 数量 |
|---|---|---|---|---|---|
| 5mg | 95% | 询价 | |||
| 25mg | 95% | 询价 | |||
| 50mg | 95% | 询价 | |||
| 100mg | 95% | 询价 | |||
| 250mg | 95% | 询价 |
CAS No. |
1507930-57-5 |
|---|---|
中文名称 |
(2S,5S,8S,11S,14S,17S)-17-((2S,3S)-2-((S)-5-氨基-2-((S)-2,6-二氨基己酰胺基)-5-氧代戊酰胺基)-3-甲基戊酰胺基)-2,8,11-三(4-氨基丁基)-5-苄基-14-((S)-仲丁基)-4,7,10,13,16-五氧代-3,6,9,12,15-五氮杂二十烷-1,20-二酸 |
英文名称 |
(2S,5S,8S,11S,14S,17S)-17-((2S,3S)-2-((S)-5-Amino-2-((S)-2,6-diaminohexanamido)-5-oxopentanamido)-3-methylpentanamido)-2,8,11-tris(4-aminobutyl)-5-benzyl-14-((S)-sec-butyl)-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazaicosane-1,20-dioic acid |
别名 |
Gap19 trifluoroacetate salt | KQIEIKKFK trifluoroacetate salt, Lys-Gln-Ile-Glu-Ile-Lys-Lys-Phe-Ly trifluoroacetate salt, L-lLysyl-L-glutaminyl-L-isoleucyl-L-α-glutamyl-L-isoleucyl-L-lysyl-L-lysyl-L-phenylalanyl--L-lysine |
标准英文名 |
L-lysyl-L-glutaminyl-L-isoleucyl-L-glutamyl-L-isoleucyl-L-lysyl-L-lysyl-L-phenylalanyl-L-lysine |
MDL No. |
MFCD30182282 |
分子式 |
C55H96N14O13 |
分子量 |
1161.46 |
精确分子量 |
1160.73 |
SMILES |
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)O |
标准SMILES |
C[C@@H](CC)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(O)=O |
用途 |
Gap19 is a selective inhibitor of connexin 43 (Cx43) hemichannels, derived from the cytoplasmic loop (CL) of Cx43; it prevents the intramolecular interaction between the C-terminus (CT) and CL without blocking gap junction (GJ) channels or Cx40/pannexin-1 hemichannels; it exhibits cardioprotective effects by reducing mitochondrial potassium uptake, inhibiting Cx43 hemichannel currents in HeLa-Cx43 cells and ventricular cardiomyocytes, and protecting against myocardial ischemia/reperfusion injury in vitro and in vivo; intravenous administration (25 mg/kg, 10 min before ligation) significantly reduces infarct size by approximately one-fifth in C57/BL6 mice. |
InChIKey |
IEAKEKFIXUZWEH-PKMKMBMKSA-N |
|
|
评论 |
|---|